Medtronic says it's launching a new directional atherectomy device called the HawkOne to treat peripheral artery disease.
Medtronic touts positive 3-year results for the EverFlex self-expanding stent for treating peripheral artery disease it acquired when it bought Covidien for $50 billion.
Here's a look at some of the top regulatory stories for medical device companies this week: Boston Scientific wins CE Mark, FDA nod for smaller 'leadless' ICD; FDA approves Biotronik's Eluna MRI-safe pacemaker; PAD: Medtronic wins expanded FDA nod for Protégé GPS stent; Australian PE shop acquires Simplify Medical
Medtronic says it won a nod from the FDA for its Protégé GPS stent to treat peripheral artery disease in the common and external iliac arteries.
Boston Scientific names former Covidien CFO Charles Dockendorff and Hologic CEO Stephen MacMillan to its board of directors.
Biolase Technology Inc.
, Boston Scientific
, Breg Inc.
, Google Inc.
, Hologic Inc.
, Penumbra Inc.
Federal regulators say they have approved the VenaSeal closure system to treat varicose veins
Covidien's VenaSeal closure system to treat varicose veins has been approved by the U.S. Food and Drug Administration, according to an agency press release.
Medtronic CEO Omar Ishrak tells analysts the company's managed services business for cath labs is expanding into new markets, with booked sales topping the $1 billion mark through its fiscal 3rd quarter.